May 1, 2024
Parexel receives ISO 22301 certifications for Durham, NC and Uxbridge, UK locations
This certification provides a framework for organizations to plan, establish, implement, operate, monitor, review, maintain and continually improve a documented management system to protect against, reduce the likelihood of, and ensure recovery from disruptive incidents.
April 3, 2024
Parexel named “Best Contract Research Organization” at the 17th Annual Vaccine Industry Excellence (ViE) awards

Parexel was selected by a distinguished industry advisory board for its range of services in niche and core therapeutic areas, methods of performance improvement, attention to and quality of relationships with clients, reaching milestones and final outcomes, and building and maintaining existing and long-term partnerships. The annual ViE Awards, organized by Terrapin, celebrate the industry’s most outstanding achievements and showcase excellence in the global vaccine industry.

March 19, 2024
Parexel's Deb Tatton Honored as a 2024 HBA Luminary
Parexel's Deb Tatton, President, Global Clinical & Data Operations has been recognized as a 2024 Luminary by the Healthcare Businesswomen's Assocation (HBA) for her almost three decades of impactful leadership, serving as a role model, actively mentoring others and driving progress in the healthcare industry.
March 1, 2024
Parexel India recognized for the fifth consecutive year at the DivHERsity Awards

Parexel India was recognized in three different categories including Top 20 Most Innovative Practices – DivHERsity Programs, Top 5 Most Innovative Practices – Women Returnee Programs, and Top 20 Companies in DivHERsity – Large Enterprises. Parexel was chosen for its exceptional work in accelerating female participation and performance through diversity programs and policies. The DivHERsity awards recognize companies in India that are committed to workplace equality for women and can demonstrate that commitment with successful DE&I initiatives, turning aspirations into reality.